chr15-90763152-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PP3_Strong
The ENST00000355112.8(BLM):c.2069C>T(p.Pro690Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000958 in 1,461,612 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. P690P) has been classified as Likely benign.
Frequency
Consequence
ENST00000355112.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BLM | NM_000057.4 | c.2069C>T | p.Pro690Leu | missense_variant | 8/22 | ENST00000355112.8 | NP_000048.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BLM | ENST00000355112.8 | c.2069C>T | p.Pro690Leu | missense_variant | 8/22 | 1 | NM_000057.4 | ENSP00000347232.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251242Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135796
GnomAD4 exome AF: 0.00000958 AC: 14AN: 1461612Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727112
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Bloom syndrome Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Aug 10, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 690 of the BLM protein (p.Pro690Leu). This variant is present in population databases (rs761589072, gnomAD 0.007%). This missense change has been observed in individual(s) with colorectal cancer (PMID: 17407155, 30871259). ClinVar contains an entry for this variant (Variation ID: 454092). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BLM protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects BLM function (PMID: 2678854, 23129629). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Nov 21, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies support a damaging effect: hypersensitivity to hydroxyurea (HU) and no significant reduction in SCE frequency or formation of quadriradical chromosomes (Mirzaei et al., 2012; Shastri et al., 2016); Observed in individuals with a personal or family history of colorectal cancer (Daz-Gay et al., 2019); This variant is associated with the following publications: (PMID: 24816114, 30871259, 17407155, 23129629, 26788541, 32704157) - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 27, 2024 | The p.P690L variant (also known as c.2069C>T), located in coding exon 7 of the BLM gene, results from a C to T substitution at nucleotide position 2069. The proline at codon 690 is replaced by leucine, an amino acid with similar properties. This alteration has been reported in the heterozygous state in an individual with Bloom syndrome. The presence of another BLM alteration in this individual is not mentioned by study authors (German J et al. Hum. Mutat., 2007 Aug;28:743-53). This alteration has demonstrated functional impairment with respect to chromosome maintenance, DNA damage response and sensitivity to DNA damaging agents (Mirzaei H et al. Proc. Natl. Acad. Sci. U.S.A., 2012 Nov;109:19357-62; Shastri VM et al. Mol Genet Genomic Med, 2016 Jan;4:106-19). This alteration has also been identified in the germline of an individual from a familial colorectal cancer cohort that underwent whole exome sequencing (Díaz-Gay M et al. Cancers (Basel), 2019 03;11:). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at